Celldex Therapeutics, Inc. — Director's Dealing 2024

Jun 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-05-30

Reporting Person: Heath-Chiozzi Margo (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-30	Common Stock	M	29068	$2.78	Acquired	41162	Direct
2024-05-30	Common Stock	M	2043	$9.0165	Acquired	43205	Direct
2024-05-30	Common Stock	M	2608	$10.38	Acquired	45813	Direct
2024-05-30	Common Stock	S	38719	$34.07	Disposed	7094	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-30	Incentive Stock Option (Right to Buy)	$2.78	M	29068	Disposed	2029-06-19	Common Stock (29068)	Direct
2024-05-30	Incentive Stock Option (Right to Buy)	$9.0165	M	2043	Disposed	2028-06-13	Common Stock (2043)	Direct
2024-05-30	Incentive Stock Option (Right to Buy)	$10.38	M	2608	Disposed	2030-06-18	Common Stock (2608)	Direct

Footnotes

F1: Includes 847 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F3: As of June 19, 2023, the option is fully vested.

F4: As of June 13, 2022, the option is fully vested.

F5: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.